Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

05.11.15	Sanofi and Hanmi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments (GlobeNewswire)
04.11.15	Sanofi and the Institut Pasteur reward four researchers for their major contributions in the service of health (GlobeNewswire)
03.11.15	Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement (GlobeNewswire)
29.10.15	Sanofi Q3 Profit Up, Warns Of Diabetes Sales Drop; Stock Down (RTTNews)
29.10.15	Sanofi Q3 Profit Surges On Higher Sales, Reaffirms 2015 Outlook - Quick Facts (RTTNews)
29.10.15	GILD Files NDA For HCV Medicine, Canada Gets MonaLisa Touch, APRI Awaits Data (RTTNews)
28.10.15	Sanofi Voluntarily Recalls All Auvi-Q (RTTNews)
08.10.15	Genzyme Reports Positive New 5-year Data From Extension Study Of Lemtrada (RTTNews)
08.10.15	Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials (GlobeNewswire)
08.10.15	Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials (Businesswire)
07.10.15	Genzyme: Aubagio Slows Brain Atrophy In People With Relapsing MS - Quick Facts (RTTNews)
07.10.15	AstraZeneca Completes Divestment Of Caprelsa To Genzyme - Quick Facts (RTTNews)
01.10.15	Sanofi Launches Authorized Generic Version Of Arava Tablets (RTTNews)
01.10.15	Genzyme Opts Into Alnylam's ALN-AT3 Hemophilia Program - Quick Facts (RTTNews)
30.09.15	Soothing Balm For Avita, NVAX Gets Booster Shot, RVNC On The Move (RTTNews)
29.09.15	Zealand Pharma Says Sanofi's NDA For Lixisenatide Accepted For Review By FDA (RTTNews)
29.09.15	Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA (GlobeNewswire)
28.09.15	Lilly,Sanofi Enter Into Settlement Agreement In U.S. Insulin Glargine Litigation (RTTNews)
28.09.15	Sanofi Reaches Patent Settlement on Lantus® SoloSTAR® (GlobeNewswire)
28.09.15	Regeneron And Sanofi Say EU Approves Praluent To Treat Hypercholesterolemia (RTTNews)
28.09.15	Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union (GlobeNewswire)
23.09.15	More Than 50 Presentations of New Data from Genzyme’s Multiple Sclerosis Franchise to be Featured at ECTRIMS (Businesswire)
16.09.15	Sanofi's CSR Achievements Recognized in the Dow Jones Sustainability Indices (GlobeNewswire)
15.09.15	Sanofi Successfully Prices EUR 2 Bln Bond Issue Across 3 Tranches (RTTNews)
15.09.15	Sanofi successfully prices EUR 2.0 billion bond issue (GlobeNewswire)
14.09.15	Zealand Pharma: LixiLan-L Trial's Successful Completion Not To Change 2015 View (RTTNews)
14.09.15	Sanofi Announces Positive Results In Second Pivotal LixiLan Phase III Study (RTTNews)
14.09.15	Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study (GlobeNewswire)
04.09.15	Genzyme To Pay $32.5 Mln To Resolve Criminal Liability Relating To Seprafilm (RTTNews)
02.09.15	FLXN On Fast Track, WMGI Gets FDA Nod, RDHL Gearing Up, NVRO Awaits D-Day (RTTNews)
01.09.15	Regeneron And Sanofi Announce New Positive Praluent Phase 3 Data Presented (RTTNews)
01.09.15	Sanofi and Regeneron Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015 (GlobeNewswire)
01.09.15	AIMT Is Nothing To Sneeze At, AGRX Secured, TiGenix Admired, ICPT Gets FDA Date (RTTNews)
31.08.15	Sanofi To Collaborate With Google To Improve Diabetes Health Outcomes (RTTNews)
31.08.15	Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes (GlobeNewswire)
10.08.15	Evotec, Apeiron, Sanofi To Develop Small Molecule-based Cancer Immunotherapies (RTTNews)
10.08.15	Sanofi, Evotec and Apeiron Biologics Enter Collaboration To Develop Novel Small Molecule Immuno-Oncology Treatments (GlobeNewswire)
07.08.15	Sanofi And Evotec Collaborate To Develop Next Generation Therapies In Diabetes (RTTNews)
07.08.15	Sanofi, Evotec Enter New Research Collaboration to Discover and Develop Novel Diabetes Therapies (GlobeNewswire)
30.07.15	Sanofi Q2 Profit Climbs; Backs FY15 Profit View - Quick Facts (RTTNews)
30.07.15	Sanofi delivers solid sales and business EPS(1) growth in Q2 2015 (GlobeNewswire)
28.07.15	Regeneron, Sanofi To Jointly Advance PD-1, Other New Immuno-oncology Antibodies (RTTNews)
28.07.15	Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration (GlobeNewswire)
27.07.15	New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue (GlobeNewswire)
27.07.15	Sanofi: Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca (GlobeNewswire)
24.07.15	Sanofi: FDA Okays Praluent To Treat Certain Patients With High Cholesterol (RTTNews)
24.07.15	Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients (GlobeNewswire)
24.07.15	Regeneron:CHMP Recommends EU Approval Of Praluent To Treat Hypercholesterolemia (RTTNews)
24.07.15	Sanofi and Regeneron Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia (GlobeNewswire)
15.07.15	Sanofi Reduces Business Units To Five To Drive Growth (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus
22.11.24		Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge
22.11.24		Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500
22.11.24		Gewinne in New York: NASDAQ 100 präsentiert sich fester
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus

22.11.24

Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge

22.11.24

Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500

22.11.24

Gewinne in New York: NASDAQ 100 präsentiert sich fester

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester